Cure Parkinson’s and Alzheimer’s Research UK announce a partnership
Cure Parkinson’s and Alzheimer’s Research UK are working on an initiative that could pave the way for innovative neurodegenerative treatments. There is a growing recognition that tackling neurodegenerative diseases could benefit from a collaborative, cross-disease approach. We are recognising the overlap in underlying biological...
Learn more
Anle138b to target the toxic protein in Parkinson’s
In Parkinson’s, a cell protein called alpha-synuclein, which is abundant in dopamine-producing nerve cells, is known to clump together (or aggregate) and it is believed that this process could be toxic. Anle138b is a small molecule that has been designed to inhibit alpha-synuclein aggregation.
Something ‘LRRK -ing’ in the data
Over recent years, researchers have been identifying genetic variations associated with an increased risk of developing Parkinson’s. A recent study has thrown further light on the connection between certain genetic risk factors and Parkinson’s progression.
Further support for diabetes treatments for Parkinson’s
A research group in South Korea has published results of their trial which provide further evidence that diabetes treatments can slow down the development of Parkinson’s in people with diabetes.
Important phase 1 trial results for LRRK2 inhibitor drug
This week the biotech company Denali Therapeutics announced the results of a phase 1 clinical trial of their LRRK2 inhibitor drug called ‘DNL151’. Their findings have interesting implications for the Parkinson’s community.
PD Avengers webinar hosted by Cure Parkinson’s: Women with Parkinson’s
Can meeting the needs of women living with Parkinson’s unlock new treatments to better manage, slow, stop or even cure Parkinson’s? Re-watch our recent webinar.